Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

Maria Vittoria Dubbinia Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyCorrespondence[email protected]
View further author information

Loredana De Marcob Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Licia Baldic Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Luana Vignoloc Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Fiorella Ilariuccia Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, ItalyView further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

The authors have no conflict of interest to declare, including specific financial interests, relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.

Additional information

Funding

This study was partially supported by Italian Ministry of Health – Ricerca Corrente Annual Program 2024. This case report has received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

Information for

Open access

Opportunities

Help and information

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature